Role of stem cells in arteriovenous access: perspective from Lower Middle Income Countries

Area of Science:

• Regenerative Medicine
• Vascular Surgery
• Nephrology

Background:

• Hemodialysis access is crucial for renal failure patients' well-being.
• Maintaining arteriovenous fistula (AVF) patency is essential for effective treatment.
• Venous neointimal hyperplasia (NIH) is a primary cause of AVF failure.

Purpose of the Study:

• To review the current role of stem cells in enhancing AVF patency.
• To explore the feasibility of utilizing stem cell therapy in resource-limited settings.
• To discuss challenges and potential strategies for implementing stem cell treatments in Pakistan.

Main Methods:

• Review of recent literature on stem cell therapy for AVF.
• Analysis of mesenchymal stromal cells (MSC) efficacy in preventing NIH.
• Discussion of economic and logistical factors for implementation in Pakistan.

Main Results:

• Mesenchymal stromal cells (MSC) have demonstrated success in preventing venous neointimal hyperplasia.
• Stem cell treatments offer a promising avenue for improving AVF longevity.
• High costs present a significant barrier to adoption in low-middle income countries.

Conclusions:

• Stem cell therapy, particularly MSC, holds significant potential for improving hemodialysis access outcomes.
• Cost-effective strategies are needed to make this advanced treatment accessible in countries like Pakistan.
• Further research and policy development are required for successful implementation.